Hubei Jumpcan Pharmaceutical Co Ltd (600566) — Capital Reinvestment Ratio
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has a Capital Reinvestment Ratio of 0.09x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥178.57 Million) in capital expenditures (CN¥15.27 Million). See how leveraged is Hubei Jumpcan Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hubei Jumpcan Pharmaceutical Co Ltd Capital Reinvestment Ratio (2000–2024)
This chart tracks Hubei Jumpcan Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 24 annual periods. Check how aggressively does Hubei Jumpcan Pharmaceutical Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Hubei Jumpcan Pharmaceutical Co Ltd (2000–2024)
Year-by-year Capital Reinvestment Ratio for Hubei Jumpcan Pharmaceutical Co Ltd from 2000 to 2024. For live market cap and broader valuation context, see market cap of Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.08x | CN¥2.18 Billion | CN¥174.34 Million | ▼ -8.0% |
| 2023 | 0.09x | CN¥3.46 Billion | CN¥301.64 Million | ▼ -6.3% |
| 2022 | 0.09x | CN¥2.62 Billion | CN¥243.66 Million | ▼ -29.1% |
| 2021 | 0.13x | CN¥1.89 Billion | CN¥248.32 Million | ▼ -45.6% |
| 2020 | 0.24x | CN¥1.78 Billion | CN¥429.63 Million | ▼ -5.2% |
| 2019 | 0.25x | CN¥2.15 Billion | CN¥546.44 Million | ▼ -34.9% |
| 2018 | 0.39x | CN¥1.71 Billion | CN¥668.06 Million | ▼ -37.7% |
| 2017 | 0.63x | CN¥1.19 Billion | CN¥746.25 Million | ▲ +77.2% |
| 2016 | 0.35x | CN¥913.10 Million | CN¥323.49 Million | ▼ -42.2% |
| 2015 | 0.61x | CN¥645.48 Million | CN¥395.98 Million | ▲ +25.4% |
| 2014 | 0.49x | CN¥616.11 Million | CN¥301.51 Million | ▼ -48.0% |
| 2013 | 0.94x | CN¥287.16 Million | CN¥270.10 Million | ▼ -43.1% |
| 2012 | 1.65x | CN¥27.01 Million | CN¥44.67 Million | ▼ -98.9% |
| 2011 | 147.69x | CN¥411.24K | CN¥60.74 Million | ▲ +9770.9% |
| 2010 | 1.50x | CN¥51.13 Million | CN¥76.50 Million | ▲ +2.4% |
| 2009 | 1.46x | CN¥4.92 Million | CN¥7.19 Million | ▲ +304.4% |
| 2008 | 0.36x | CN¥23.05 Million | CN¥8.33 Million | ▲ +69.4% |
| 2007 | 0.21x | CN¥36.72 Million | CN¥7.83 Million | ▼ -98.3% |
| 2006 | 12.22x | CN¥4.24 Million | CN¥51.83 Million | ▲ +1194.8% |
| 2005 | 0.94x | CN¥63.38 Million | CN¥59.80 Million | ▼ -94.7% |
| 2003 | 17.83x | CN¥2.24 Million | CN¥39.99 Million | ▲ +235.0% |
| 2002 | 5.32x | CN¥22.00 Million | CN¥117.09 Million | ▼ -55.1% |
| 2001 | 11.86x | CN¥7.43 Million | CN¥88.07 Million | ▲ +1349.6% |
| 2000 | 0.82x | CN¥23.73 Million | CN¥19.41 Million | — |